Elena P Kuz, RN in Ava, MO - Registered Nurse

Elena P Kuz, RN is a Registered Nurse based in Ava, Missouri. Elena P Kuz is licensed to practice in Missouri (license number 2021002615) and her current practice location is 119 S Jefferson St, Ava, Missouri. She can be reached at her office (for appointments etc.) via phone at (417) 683-2786.

NPI number for Elena P Kuz is 1629842927 and her current mailing address is 1601 Old South River Rd, Saint Charles, Missouri. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1629842927.

Contact Information

	Elena P Kuz, RN
	119 S Jefferson St, Ava, MO 65608-5530
	(417) 683-2786
	Not Available

Provider's Profile

Full Name	Elena P Kuz
Gender	Female
Speciality	Registered Nurse
Location	119 S Jefferson St, Ava, Missouri
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1629842927
Provider Enumeration Date: 11/08/2023
Last Update Date: 11/08/2023

Medical Identifiers

Medical identifiers for Elena P Kuz such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1629842927	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
163W00000X	Registered Nurse	2021002615 (Missouri)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Elena P Kuz is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Elena P Kuz, RN 1601 Old South River Rd, Saint Charles, MO 63303-4120 Ph: (636) 224-1210	Elena P Kuz, RN 119 S Jefferson St, Ava, MO 65608-5530 Ph: (417) 683-2786

News Archive

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has successfully completed enrollment and treatment of the last patient in its Phase I clinical trial of CUDC-101, Curis' first-in-class HDAC, EGFR and HER2 inhibitor.

New class of targeted cancer drugs may prove effective in treating common types of leukemia

A new study by researchers in Cleveland Clinic's Taussig Cancer Institute and Lerner Research Institute describes a novel class of targeted cancer drugs that may prove effective in treating certain common types of leukemia.

Spyryx receives award from Cystic Fibrosis Foundation to development therapeutic peptides for CF

Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for obstructive lung diseases, announced today it has received an award from Cystic Fibrosis Foundation Therapeutics, which will support development of Spyryx' therapeutic peptides for cystic fibrosis (CF).

Use of dicloxacillin linked to INR decrease in patients taking vitamin K antagonists

Researchers have found an association between treatment with the antibiotic dicloxacillin and a decrease in international normalized ratio (INR; a measure of blood coagulation) levels among patients taking the vitamin K antagonists warfarin or phenprocoumon, according to a study in the July 21 issue of JAMA.

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

Elena P Kuz, RN - Registered Nurse in Ava, MO